用于乳腺癌个性化免疫治疗的免疫肿瘤生物标志物
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer.
作者信息
Vafaizadeh Vida, Barekati Zeinab
机构信息
Department of Biomedicine, University of Basel, Basel, Switzerland.
出版信息
Front Cell Dev Biol. 2020 Mar 17;8:162. doi: 10.3389/fcell.2020.00162. eCollection 2020.
Abstract
The immune checkpoint blockade therapy has drastically advanced treatment of different types of cancer over the past few years. Female breast cancer is the second leading cause of death in the overall burden of cancers worldwide that is encouraging healthcare professionals to improve cancer care management. The checkpoint blockade therapies combined with novel agents become the recent focus of various clinical trials in breast cancer. However, identification of the patients who are responsive to these therapeutic strategies remained as a major issue for enhancing the efficacy of these treatments. This highlights the unmet need in discovery and development of novel biomarkers to add predictive values for prosperous personalized medicine. In this review we summarize the advances done in the era of biomarker studies and highlight their link in supporting breast cancer immunotherapy.
摘要
在过去几年中，免疫检查点阻断疗法极大地推动了不同类型癌症的治疗。女性乳腺癌是全球癌症总负担中第二大死因，这促使医疗保健专业人员改善癌症护理管理。检查点阻断疗法与新型药物联合使用已成为乳腺癌各种临床试验的近期焦点。然而，确定对这些治疗策略有反应的患者仍然是提高这些治疗效果的一个主要问题。这凸显了在发现和开发新型生物标志物以增加预测价值以实现繁荣的个性化医疗方面未满足的需求。在这篇综述中，我们总结了生物标志物研究时代所取得的进展，并强调它们在支持乳腺癌免疫治疗方面的联系。
相似文献
1
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer.用于乳腺癌个性化免疫治疗的免疫肿瘤生物标志物
Front Cell Dev Biol. 2020 Mar 17;8:162. doi: 10.3389/fcell.2020.00162. eCollection 2020.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?优化癌症免疫疗法：是否到了采用个体化预测性生物标志物的时候？
Crit Rev Clin Lab Sci. 2018 Nov;55(7):466-479. doi: 10.1080/10408363.2018.1499706. Epub 2018 Oct 2.
4
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
5
Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
6
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.乳腺癌治疗的免疫疗法：检查点阻断、癌症疫苗及联合免疫疗法的未来方向
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.
7
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.抗 PD-1/PD-L1 治疗非小细胞肺癌：迈向个体化医学和联合策略。
J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018.
8
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
9
Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.联合治疗策略提高 PD-1 阻断疗效：癌症免疫治疗的新时代。
J Intern Med. 2018 Feb;283(2):110-120. doi: 10.1111/joim.12708. Epub 2017 Nov 16.
10
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).个性化医学和肿瘤免疫时代临床试验的变化：国际肿瘤学和血液肿瘤学临床试验大会（ICTO 2017）报告。
J Exp Clin Cancer Res. 2017 Dec 28;36(1):192. doi: 10.1186/s13046-017-0668-0.
引用本文的文献
1
Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model.凯林肽与树突状细胞疫苗在4T-1小鼠乳腺癌模型中的协同抗肿瘤作用
Vaccines (Basel). 2025 May 28;13(6):577. doi: 10.3390/vaccines13060577.
2
KLK7 Involvement in Thyroid Papillary Carcinoma Cell Migration and Invasion by EMT via MAPK/ERK Pathways.KLK7通过MAPK/ERK信号通路介导上皮-间质转化参与甲状腺乳头状癌细胞的迁移和侵袭
J Cancer. 2025 Feb 11;16(5):1709-1725. doi: 10.7150/jca.101555. eCollection 2025.
3
NSUN7 promotes cervical cancer progression through activation of ErbB signaling pathway.NSUN7通过激活ErbB信号通路促进宫颈癌进展。
Funct Integr Genomics. 2025 Feb 15;25(1):37. doi: 10.1007/s10142-025-01546-9.
4
Harnessing IL-27: challenges and potential in cancer immunotherapy.利用白细胞介素-27：癌症免疫治疗中的挑战与潜力
Clin Exp Med. 2025 Jan 11;25(1):34. doi: 10.1007/s10238-025-01562-w.
5
Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model.靶向 Dectin-1 和/或 VISTA 可增强黑色素瘤而非结直肠癌模型的抗肿瘤免疫。
Cell Oncol (Dordr). 2024 Oct;47(5):1735-1756. doi: 10.1007/s13402-024-00950-w. Epub 2024 Apr 26.
6
Regression-based Deep-Learning predicts molecular biomarkers from pathology slides.基于回归的深度学习从病理切片中预测分子生物标志物。
Nat Commun. 2024 Feb 10;15(1):1253. doi: 10.1038/s41467-024-45589-1.
7
Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.揭示乳腺癌免疫微环境的作用：窥探充满希望的前沿领域。
Int J Mol Sci. 2023 Oct 18;24(20):15332. doi: 10.3390/ijms242015332.
8
MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.MCM10：子宫体子宫内膜癌患者的有效治疗靶点和预后生物标志物。
J Cell Mol Med. 2023 Jun;27(12):1708-1724. doi: 10.1111/jcmm.17772. Epub 2023 May 29.
9
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.晚期癌症患者接受免疫检查点抑制剂治疗时血液胆固醇质量的作用。
Cancer Immunol Immunother. 2023 Jul;72(7):2127-2135. doi: 10.1007/s00262-023-03398-3. Epub 2023 Feb 24.
10
Pro-Inflammatory and Anti-Inflammatory Salivary Cytokines in Breast Cancer: Relationship with Clinicopathological Characteristics of the Tumor.乳腺癌中促炎和抗炎唾液细胞因子：与肿瘤临床病理特征的关系
Curr Issues Mol Biol. 2022 Oct 6;44(10):4676-4691. doi: 10.3390/cimb44100319.
本文引用的文献
1
Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer.循环 microRNAs 可预测非小细胞肺癌对抗 PD-1 治疗的反应。
Genomics. 2020 Mar;112(2):2063-2071. doi: 10.1016/j.ygeno.2019.11.019. Epub 2019 Nov 28.
2
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.转移性乳腺癌的基因组景观突出了突变和特征频率的变化。
Nat Genet. 2019 Oct;51(10):1450-1458. doi: 10.1038/s41588-019-0507-7. Epub 2019 Sep 30.
3
Circulating Tumor Cell-Neutrophil Tango along the Metastatic Process.循环肿瘤细胞-中性粒细胞的共舞与转移过程。
Cancer Res. 2019 Dec 15;79(24):6067-6073. doi: 10.1158/0008-5472.CAN-19-1972. Epub 2019 Sep 16.
4
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.程序性死亡受体 1（PD-1）阻断治疗的癌症患者中微卫星不稳定性和高肿瘤突变负荷的无创检测
Clin Cancer Res. 2019 Dec 1;25(23):7024-7034. doi: 10.1158/1078-0432.CCR-19-1372. Epub 2019 Sep 10.
5
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.免疫组织化学检测 PD-L1 可互换性的荟萃分析：诊断准确性评估。
Mod Pathol. 2020 Jan;33(1):4-17. doi: 10.1038/s41379-019-0327-4. Epub 2019 Aug 5.
6
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers.用于检测非小细胞肺癌耐药机制的液体活检：不同血液生物标志物的比较
J Clin Med. 2019 Jul 9;8(7):998. doi: 10.3390/jcm8070998.
7
A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma.四项 DNA 甲基化生物标志物可更好地预测皮肤黑素瘤患者的生存情况。
Elife. 2019 Jun 6;8:e44310. doi: 10.7554/eLife.44310.
8
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.错配修复缺陷/微卫星不稳定高作为抗 PD-1/PD-L1 免疫治疗疗效的预测指标。
J Hematol Oncol. 2019 May 31;12(1):54. doi: 10.1186/s13045-019-0738-1.
9
Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.cfDNA 分析检测乳腺癌单核苷酸变异和拷贝数变异的准确性。
BMC Cancer. 2019 May 17;19(1):465. doi: 10.1186/s12885-019-5698-x.
10
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.肿瘤内 CXCR3 趋化因子系统的活性是抗 PD-1 治疗疗效所必需的。
Immunity. 2019 Jun 18;50(6):1498-1512.e5. doi: 10.1016/j.immuni.2019.04.010. Epub 2019 May 13.
Zotero 插件